Document Type : Original Research


1 Oncopathology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran

2 Department of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran

3 Department of Pathology and Genomic Medicine, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA

4 Clinical Research Development Unit of Ayatollah-Khansari Hospital, Arak University of Medical Sciences, Arak, Iran

5 Department of Pathology, Iran University of Medical Sciences, Tehran, Iran

6 Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran

7 Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran

8 Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran

9 Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran


Background & Objective: Talin-1 is a constituent of the multiprotein adhesion complexes that play  main role in the formation of tumors and migration in different types of malignancies. The present study aimed to assess  expression and prognostic significance of the talin-1 protein in ovarian serous carcinoma (OSC) patients.
Methods: The expression of talin-1 in mRNA and its protein levels were investigated for ovarian cancer (OC) by using bioinformatics tools, including Gene Expression Profiling Interactive Analysis 2 (GEPIA2), Gene Expression Database of Normal and Tumor Tissue 2 (GENT2), and The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN) databases. Thereafter, immunohistochemical (IHC) staining was used to study the expression patterns of the talin-1 protein using 46 paraffin-embedded OSC tissue specimens, 25 benign tumors, and 20 normal tissues, which were assembled in tissue microarrays (TMAs). We also assessed the potential association between the expression of the talin-1 protein, various clinicopathological parameters, and survival outcomes.
Results: Our IHC examination for talin-1 was significantly overexpressed in OSC tissues compared to benign tumors and normal tissues. The Kaplan-Meier survival analysis has also indicated statistically significant differences in terms of disease-specific survival (DSS) and progression-free survival (PFS) between the patients with high and low expression levels of talin-1, respectively.
Conclusion: The talin-1 protein was overexpressed in OSC tissues, and a high expression level of talin-1 was found to be significantly associated with tumor aggressiveness and poorer DSS or PFS. Therefore, talin-1 may serve as a molecular marker of cancer progression and a novel prognostic biomarker in these patients.


Main Subjects

  1. Rock CL, Thomson C, Gansler T, Gapstur SM, McCullough ML, Patel AV, et al. American Cancer Society guideline for diet and physical activity for cancer prevention. CA Cancer J Clin. 2020;70(4):245-71. [DOI:10.3322/caac.21591] [PMID]
  2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. [DOI:10.1002/ijc.29210] [PMID]
  3. Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, et al. Cell Origins of High-Grade Serous Ovarian Cancer. Cancers (Basel). 2018;10(11). [DOI:10.3390/cancers10110433] [PMID] [PMCID]
  4. Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, et al. Epithelial ovarian cancer: An overview. World J Transl Med. 2014;3(1):1-8. [DOI:10.5528/wjtm.v3.i1.1] [PMID] [PMCID]
  5. Muinao T, Deka Boruah HP, Pal M. Multi-biomarker panel signature as the key to diagnosis of ovarian cancer. Heliyon. 2019;5(12):e02826. [DOI:10.1016/j.heliyon.2019.e02826] [PMID] [PMCID]
  6. Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A. Potential markers for detection and monitoring of ovarian cancer. J Oncol. 2011;2011:475983. [DOI:10.1155/2011/475983] [PMID] [PMCID]
  7. Klapholz B, Brown NH. Talin - the master of integrin adhesions. J Cell Sci. 2017;130(15):2435-46. [DOI:10.1242/jcs.190991] [PMID]
  8. Malla RR, Vempati RK. Talin: A Potential Drug Target for Cancer Therapy. Curr Drug Metab. 2020;21(1):25-32. [DOI:10.2174/1389200221666200214114018] [PMID]
  9. Kanamori H, Kawakami T, Effendi K, Yamazaki K, Mori T, Ebinuma H, et al. Identification by differential tissue proteome analysis of talin-1 as a novel molecular marker of progression of hepatocellular carcinoma. Oncology. 2011;80(5-6):406-15. [DOI:10.1159/000330734] [PMID]
  10. Tang H, Yao L, Tao X, Yu Y, Chen M, Zhang R, et al. miR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting TLN1. Int J Mol Med. 2013;32(2):381-8. [DOI:10.3892/ijmm.2013.1400] [PMID]
  11. Wang J, Zhou H, Wang K, Shang X, Chen X, Zheng L, et al., editors. Expression of Talin 1 in tissues of ovarian cancer and its role in invasion and migration of ovarian cancer cells2016.
  12. Lai MT, Hua CH, Tsai MH, Wan L, Lin YJ, Chen CM, et al. Talin-1 overexpression defines high risk for aggressive oral squamous cell carcinoma and promotes cancer metastasis. J Pathol. 2011;224(3): 367-76. [DOI:10.1002/path.2867] [PMID]
  13. Xu YF, Ren XY, Li YQ, He QM, Tang XR, Sun Y, et al. High expression of Talin-1 is associated with poor prognosis in patients with nasopharyngeal carcinoma. BMC Cancer. 2015;15:332. [DOI:10.1186/s12885-015-1351-5] [PMID] [PMCID]
  14. Vafaei S, Saeednejad Zanjani L, Habibi Shams Z, Naseri M, Fattahi F, Gheytanchi E, et al. Low expression of Talin1 is associated with advanced pathological features in colorectal cancer patients. Sci Rep. 2020;10(1):17786. [PMID] [PMCID] [DOI:10.1038/s41598-020-74810-6]
  15. Zhang JL, Qian YB, Zhu LX, Xiong QR. Talin1, a valuable marker for diagnosis and prognostic assessment of human hepatocelluar carcinomas. Asian Pac J Cancer Prev. 2011;12(12):3265-9.
  16. Slater M, Cooper M, Murphy CR. The cytoskeletal proteins alpha-actinin, Ezrin, and talin are De-expressed in endometriosis and endometrioid carcinoma compared with normal uterine epithelium. Appl Immunohistochem Mol Morphol. 2007;15(2):170-4. [PMID] [DOI:10.1097/01.pai.0000194762.78889.26]
  17. Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556-W60. [DOI:10.1093/nar/gkz430] [PMID] [PMCID]
  18. Park SJ, Yoon BH, Kim SK, Kim SY. GENT2: an updated gene expression database for normal and tumor tissues. BMC Med Genomics. 2019;12(Suppl 5):101. [DOI:10.1186/s12920-019-0514-7] [PMID] [PMCID]
  19. Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18-27. [DOI:10.1016/j.neo.2022.01.001] [PMID] [PMCID]
  20. Chow SC, Shao J, Wang H. Sample Size Calculations in Clinical Research, Second Edition. Boca Raton, Florida: Chapman & Hall/CRC; 2008.
  21. Kobel M, Kang EY. The Evolution of Ovarian Carcinoma Subclassification. Cancers (Basel). 2022;14(2). [DOI:10.3390/cancers14020416] [PMID] [PMCID]
  22. Bhatla N, Denny L. FIGO Cancer Report 2018. Int J Gynaecol Obstet. 2018;143 Suppl 2:2-3. [DOI:10.1002/ijgo.12608] [PMID]
  23. Kalantari E, Asgari M, Nikpanah S, Salarieh N, Asadi Lari MH, Madjd Z. Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas. Pathol Oncol Res. 2017;23(4):793-802. [DOI:10.1007/s12253-016-0169-z] [PMID]
  24. Kalantari E, Saadi FH, Asgari M, Shariftabrizi A, Roudi R, Madjd Z. Increased Expression of ALDH1A1 in Prostate Cancer is Correlated With Tumor Aggressiveness: A Tissue Microarray Study of Iranian Patients. Appl Immunohistochem Mol Morphol. 2017;25(8):592-8. [DOI:10.1097/PAI.0000000000000343] [PMID]
  25. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80(12):1943-9. [DOI:10.1038/labinvest.3780204] [PMID]
  26. Madjd Z, Ramezani B, Molanae S, Asadi-Lari M. High expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas. Asian Pac J Cancer Prev. 2012;13(6):2973-8. [DOI:10.7314/APJCP.2012.13.6.2973] [PMID]
  27. Erfani E, Roudi R, Rakhshan A, Sabet MN, Shariftabrizi A, Madjd Z. Comparative expression analysis of putative cancer stem cell markers CD44 and ALDH1A1 in various skin cancer subtypes. Int J Biol Markers. 2016;31(1):e53-61. [DOI:10.5301/jbm.5000165] [PMID]
  28. Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, et al. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med. 2019;8(16):7018-31. [DOI:10.1002/cam4.2560] [PMID] [PMCID]
  29. Zheng H, Zhang G, Zhang L, Wang Q, Li H, Han Y, et al. Comprehensive Review of Web Servers and Bioinformatics Tools for Cancer Prognosis Analysis. Front Oncol. 2020;10:68. [PMID] [PMCID] [DOI:10.3389/fonc.2020.00068]
  30. Wang J, Zhou H, Wang K, Shang X, Chen X, Zheng L, et al. Expression of Talin1 in tissues of ovarian cancer and its role in invasion and migration of ovarian cancer cells. International Journal of Clinical and Experimental Medicine. 2017;10:410-7.
  31. Ji L, Jiang F, Cui X, Qin C. Talin1 knockdown prohibits the proliferation and migration of colorectal cancer cells via the EMT signaling pathway. Oncol Lett. 2019;18(5):5408-16. [DOI:10.3892/ol.2019.10902] [PMID] [PMCID]
  32. Xu N, Chen HJ, Chen SH, Xue XY, Chen H, Zheng QS, et al. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer. Medicine (Baltimore). 2016;95(29):e4326. [DOI:10.1097/MD.0000000000004326] [PMID] [PMCID]
  33. Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol. 2015;213(3):262-7. [DOI:10.1016/j.ajog.2015.03.044] [PMID]
  34. Henson DE, Chu KC, Levine PH. Histologic grade, stage, and survival in breast carcinoma: comparison of African American and Caucasian women. Cancer. 2003;98(5):908-17. [DOI:10.1002/cncr.11558] [PMID]
  35. Lin NC, Hsu JT, Tsai KY. Survival and clinicopathological characteristics of different histological grades of oral cavity squamous cell carcinoma: A single-center retrospective study. PLoS One. 2020;15(8):e0238103. [DOI:10.1371/journal.pone.0238103] [PMID] [PMCID]
  36. Desiniotis A, Kyprianou N. Significance of talin in cancer progression and metastasis. Int Rev Cell Mol Biol. 2011;289:117-47. [DOI:10.1016/B978-0-12-386039-2.00004-3] [PMID] [PMCID]
  37. Bostanci O, Kemik O, Kemik A, Battal M, Demir U, Purisa S, et al. A novel screening test for colon cancer: Talin-1. Eur Rev Med Pharmacol Sci. 2014;18(17):2533-7. [DOI:10.1155/2014/161954] [PMID] [PMCID].